

Robert R McWilliams

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6319157/publications.pdf>

Version: 2024-02-01

21
papers

810
citations

566801

15
h-index

713013

21
g-index

21
all docs

21
docs citations

21
times ranked

1433
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Proband on Concomitant Risk to First-Degree Relatives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 372-381.	1.1	3
2	Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. <i>Clinical Cancer Research</i> , 2022, 28, 3021-3031.	3.2	32
3	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	3.2	32
4	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	1.5	2
5	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. <i>JCO Oncology Practice</i> , 2021, 17, e1382-e1393.	1.4	5
6	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6505-6512.	3.2	24
7	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545.	2.0	27
8	<i>CDKN2A</i> Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1364-1370.	1.1	23
9	North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. <i>Cancer</i> , 2017, 123, 3494-3501.	2.0	32
10	Prevalence of <i>CDKN2A</i> mutations in pancreatic cancer patients: implications for genetic counseling. <i>European Journal of Human Genetics</i> , 2011, 19, 472-478.	1.4	112
11	Obesity adversely affects survival in pancreatic cancer patients. <i>Cancer</i> , 2010, 116, 5054-5062.	2.0	81
12	Polymorphic Variants in Hereditary Pancreatic Cancer Genes Are Not Associated with Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2549-2552.	1.1	9
13	Nucleotide Excision Repair Pathway Polymorphisms and Pancreatic Cancer Risk: Evidence for role of <i>MMS19L</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1295-1302.	1.1	42
14	Melanoma-induced brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 743-755.	1.1	23
15	Polymorphisms in DNA Repair Genes, Smoking, and Pancreatic Adenocarcinoma Risk. <i>Cancer Research</i> , 2008, 68, 4928-4935.	0.4	102
16	Phase II Trial of Oxaliplatin/Irinotecan/5-Fluorouracil/Leucovorin for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 516-521.	1.0	6
17	Association of Family History of Specific Cancers With a Younger Age of Onset of Pancreatic Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1143-1147.	2.4	22
18	Novel Therapeutics in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1632-1650.	0.7	20

#	ARTICLE	IF	CITATIONS
19	Treatment options for brain metastases from melanoma. Expert Review of Anticancer Therapy, 2005, 5, 809-820.	1.1	14
20	Management of brain metastases from thyroid carcinoma. Cancer, 2003, 98, 356-362.	2.0	158
21	Treatment of Brain Metastases From Melanoma. Mayo Clinic Proceedings, 2003, 78, 1529-1536.	1.4	41